Here you can find more guidelines and information on HIV/AIDS.

Prevention, early diagnosis, and effective treatment are essential for the control and elimination of Neisseria gonorrhoeae as a public health problem. Currently, in Latin America and the Caribbean, treatment for gonorrhea infection is largely empiric and based on clinical diagnosis. In the Americas, the high burden of new N. gonorrhoeae infections (estimated at 11 million new cases a year), the complexity of the disease epidemiology, and in many countries the limited resources, make it difficult to fully understand the burden of disease and the burden of antimicrobial resistance (AMR) in N. gonorrhoeae. PAHO has developed this document to facilitate the navigation of available guidance and recommendations for N. gonorrhoeae AMR surveillance by public health and health care professionals, at the national and subnational levels, involved in designing, implementing, and/or strengthening AMR surveillance of N. gonorrhoeae and overall surveillance of sexually transmitted infections

Accessed on 28.02.2020

Developed by the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission— A Working Group of the Office of AIDS Research Advisory Council (OARAC) Accessed: 12.02.202

Las infecciones de transmisión sexual (ITS) constituyen un importante problema de salud pública en todo el mundo, que afecta a la calidad de vida y se acompaña de importantes niveles de morbilidad y mortalidad. Estas infecciones influyen directamente en la salud infantil y reproductiva porque traen consigo infertilidad, cánceres y complicaciones del embarazo. También tienen una influencia indirecta porque facilitan la transmisión por vía sexual del virus de la inmunodeficiencia humana (VIH), pesando así igualmente en la economía de los países y las personas. Cada día, más de un millón de personas contraen una infección de transmisión sexual. Se calcula que en 2012 hubo en el mundo 357 millones de nuevos casos de ITS curables (blenorragia, clamidiasis, sífilis o tricomoniasis) que afectaron a adultos de entre 15 y 49 años de edad, entre ellos 5,6 millones de casos de sífilis. El número de casos prevalentes de sífilis asciende, según las estimaciones, a unos 18 millones

Policy brief. These consolidated guidelines bring together existing and new evidence-based guidance and recommendations for delivering high-impact HIV testing services, including linkage to HIV prevention and treatment, in diverse settings and populations. A key objective of these guidelines is to encourage greater national and global commitment to implementing effective and efficient HTS as a vital element of the national and global HIV response, essential to achieving and maintaining low HIV incidence

Provide guidance to HIV care practitioners on the optimal use of antiretroviral (ARV) agents for the treatment of HIV infection in adults and adolescents.

Version 10.0 October 2019 These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website. The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview table of all major issues in PLWH, recommendations on antiretroviral treatment, drug-drug interactions, diagnosis, monitoring and treatment of co-morbidities, co-infections and opportunistic diseases. Available in English, French, Spanish, German, Portuguese, Russian, Chinese and Japanes

July 2019 Policy brief HIV Treatment

Updated guidelines